Indeed, it has been reported that phosphorylated IGF-1R/1R is detected in all breast cancer subtypes (luminal, 48.1%; TNBC, 41.9%; HER2, 64.3%), with higher mortality [23]. Here, ERBB2 is linked to breast carcinoma.